Analysis of FDA-approved imaging agents.
Kinch M.S. and Woodard P.K. (2017) “Analysis of FDA-approved imaging agents.” Drug Discov Today. 2017 Jul;22(7):1077-1083. doi: 10.1016/j.drudis.2017.03.006. Epub 2017 Mar 21. (Abstract)
Category: All Publications
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
Spaulding C.N., Klein R.D., Ruer S., Kau A.L., Schreiber H.L., Cusumano Z.T., Dodson K.W., Pinkner J.S., Fremont D.H., Janetka J.W., Remaut H., Gordon J.I., & Hultgren S.J. (2017). “Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.” Nature. 2017 Jun 22;546(7659):528-532. doi: 10.1038/nature22972. Epub 2017 Jun 14. (Abstract)
Technical Advance: New in vitro method for assaying the migration of primary B cells using an endothelial monolayer as substrate.
Stewart-Hutchinson P.J., Szasz T.P., Jaeger E.R., Onken M.D., Cooper J.A., & Morley S.C. (2017). “Technical Advance: New in vitro method for assaying the migration of primary B cells using an endothelial monolayer as substrate.” J Leukoc Biol. 2017 Sep;102(3):941-948. doi: 10.1189/jlb.1TA0117-008R. Epub 2017 Jun 21. (Abstract)
Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators.
Hart K.M., Moeder K.E., Ho C.M.W., Zimmerman M.I., Frederick T.E., & Bowman G.R. (2017). “Designing small molecules to target cryptic pockets yields both positive and negative allosteric modulators.” PLoS One. 2017 Jun 1;12(6):e0178678. doi: 10.1371/journal.pone.0178678. eCollection 2017. (Abstract)
A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions.
Frieden C., Wang H., & Ho C.M.W. (2017). “A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions.” Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):6292-6297. doi: 10.1073/pnas.1705080114. Epub 2017 May 30. (Abstract)
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
Owusu B.Y., Thomas S., Venukadasula P., Han Z., Janetka J.W., Galemmo R.A. Jr., & Klampfer L. (2017). “Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.” Oncotarget. 2017 May 29;8(38):63014-63025. doi: 10.18632/oncotarget.18260. eCollection 2017 Sep 8. (Abstract)
Deamidation slows Curli Amyloid-Protein Aggregation.
Wang H., Shu Q., Frieden C., & Gross M.L. (2017). “Deamidation slows Curli Amyloid-Protein Aggregation.” Biochemistry. 2017 Jun 13;56(23):2865-2872. doi: 10.1021/acs.biochem.7b00241. Epub 2017 May 26. (Abstract)
Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease.
Mydock-McGrane L.K., Hannan T.J., & Janetka J.W. (2017). “Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease.” Expert Opin Drug Discov. 2017 Jul;12(7):711-731. doi: 10.1080/17460441.2017.1331216. Epub 2017 Jun 2. (Abstract)
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
Owusu B.Y., Galemmo R., Janetka J., & Klampfer L. (2017). “Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.” Cancers (Basel). 2017 Apr 17;9(4). pii: E35. doi: 10.3390/cancers9040035. (Abstract)
Quantifying allosteric communication via both concerted structural changes and conformational disorder with CARDS
Singh S. & Bowman G.R. (2017). “Quantifying Allosteric Communication via Both Concerted Structural Changes and Conformational Disorder with CARDS.” J Chem Theory Comput. 2017 Apr 11;13(4):1509-1517. doi: 10.1021/acs.jctc.6b01181. Epub 2017 Mar 22. (Abstract)